New research released in the BMJ.

A nine year-old woman with aHUS needing plasma exchange was switched to treatment with Soliris . Nine a few months after beginning Soliris, kidney function remained stable, anti-hypertensive medications were decreased, cardiac thickening was decreased, and quality of life was improved. A renal biopsy performed at 8 weeks after starting Soliris demonstrated that there is no proof TMA. Remission of Plasma-Resistant Atypical Hemolytic Uremic Syndrome Relapse on Kidney Graft with Eculizumab, G. Ardissino. A six year-older boy with aHUS received a kidney transplant. Two months after the transplant, aHUS exacerbated without any apparent antecedent precipitant resulting in kidney failure requiring dialysis, despite plasma exchange. Soliris treatment was was and commenced associated with improvement in kidney function allowing cessation of dialysis.Secondary end points were two or fewer recurrences of cutaneous lesions through the first 12 a few months of age and detection by PCR assay of HSV DNA in the cerebrospinal fluid during or after suppressive therapy. The tertiary end stage was toxic effects of grade 2 or more, as assessed by using the World Health Organization Toxicity Grading Scale.13 All of the infants completed a 14-day course or a 21-day course of parenteral acyclovir, as may be the standard of care.14 Infants in both studies were randomly assigned then, in a 1:1 ratio, to oral placebo or acyclovir, in a double-blind fashion. The study drug was administered at a dosage of 300 mg per square meter of body-surface area, administered 3 x for 6 months daily.15 Per protocol, after an infant had a second cutaneous recurrence , the designated oral acyclovir or placebo was discontinued randomly, and open-label oral acyclovir suppression was allowed.